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Abstract To investigate the follow-up of the 17 patients
during the period of 1995–2001 of the outpatient Clinic for
Rheumatology at the University Hospital of Zurich with
arthritis and the presence of parvovirus B19 DNA demon-
strated by PCR in synovial biopsies. Seventeen patients of
163 with arthritis, which were routinely examined by nee-
dle arthroscopy during 1995–2001 with a positive parvovi-
rus B19 DNA by PCR of synovial biopsy were reevaluated.
Investigations included medical history, clinical examina-
tion and blood tests. Joint Xuid was taken on patients with
joint eVusion. The observation period of the 17 patients
(F:M = 11:6) was 2–8 years (Ø = 6.5 years). In 8 of 17
patients the arthritis could not be classiWed neither at entry
nor during the follow up of the study. The arthritis could be
diagnosed in six patients early in the onset of the disease
and included three cases of lyme arthritis of the knee joint,
two cases with arthritis following a gastrointestinal infec-
tion (one with Salmonella typhimurium—positive faecal
test—and the other one with a culture negative agent), one
patient probably had an infection-associated arthritis after a
gastrointestinal infection with Entamöeba histolytica
(Schirmer et al. in Rheumatol Int 18:37–38, 1998; Kasliwal
in Am J Proctol Gastroenterol Colon Rectal Surg 32:12, 16,
28, 1981; Haslock and Wright in J R Coll Phys Lond
8:1554–162, 1974; Than-Saw et al. in Trop Geogr Med
44:355–358, 1992) with remission after antibiotic therapy.
After a disease course of 9 months one patient could be
classiWed as rheumatoid arthritis in the presence of anti-
cyclic citrullinated antibodies but lack of rheumatoid factor.
One patient with polyarthritis developed psoriasis of the
skin 22 months later. From the nine patients with unclassi-
Wed arthritis 4 (45%) got into complete remission with no
symptoms or signs of joint inXammation after a disease
course of 9–45 months, whereas 5 (55%) still demonstrate
active non erosive arthritis (disease duration between 3 and
10 years). The presence of parvovirus B19 DNA in syno-
vial tissue of patients with joint inXammation does not
allow the diagnosis of parvovirus induced arthritis. If the
arthritis remains unclassiWed and without erosions over
time a virus associated aetiology may be assumed. How-
ever, no deWnitive diagnosis is possible even in the pres-
ence of parvovirus B19 DNA in synovial tissue.
Keywords Parvovirus B19 · Arthritis · 
Needlearthroscopy · Synovial membrane
Introduction
Parvovirus B19 was discovered in 1975 in the blood of a
healthy blood donor. It is a one-strand 5,600 base-long
DNA virus, classiWed as an erythrovirus from the family of
parvoviridae.
With a diameter of 2–26 nm it is one of the smallest
viruses. The virus capsid is not surrounded by an outside
membrane. It is extremely stable and infects preferably the
precursor cells of the erythrocytes. Propagation occurs
through droplets. It is mainly known as the cause of ery-
thema infectiosum in children, causing mild fever and skin
rash. A parvovirus B19 infection seldom occurs in adults,
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seropositivity was found in about 50% of young adults (10–
20 years) and even up to 80% in the age of 70–80 years.
The disease appears in normal individuals with exanthema,
transient thrombo- and granulocytopenia as well as arthritis
or arthralgias, less often includes persistent cytopenia, hep-
atitis or myocarditis [1–4]. 
In individuals with any disorder of the immune system
the infection can lead to a chronic persistent anaemia,
aplastic crises do also occur. An infection during pregnancy
often results in hydrops faetalis, intrauterine death or mis-
carriage, regardless of whether the mother develops clinical
symptoms or not [5, 6].
All joints may be aVected in parvovirus B19-induced
arthritis, although it most commonly involves the small
joints of the hand (namely PIP and MCP) and feet, knee,
ankle and wrist joints. The joint pattern is usually symmet-
rical, polyarticular and often self-limiting after several
weeks or months [7, 8]. There is no single test available to
reliably link an arthritis to a parvovirus B19 infection. The
diagnostic evaluation is based on clinical signs, serology
(IgM and IgG), PCR tests of serum, joint samples and bone
marrow. The signiWcance of detectable B19 DNA by PCR
in joint Xuid and synovial membrane remains unclear.
The parvovirus B19 DNA genome has been found in
healthy individuals with joint trauma as well as in patients
with juvenile chronic arthritis [7]. The same is true for
patients with rheumatoid arthritis and osteoarthritis [9, 10].
The possibility of selective antibody failure to produce neu-
tralising antibodies was evoked to explain the persistence
of chronic arthritis [11].
The objective of this study was to examine the follow-up
of patients with the presence of parvovirus B19 DNA in the
synovial membrane. Of particular interest were the duration
of the arthritis, the occurrence of erosions and the question
whether the arthritis could be classiWed over time.
Patients and methods
We examined 17 patients, 11 women and 6 men, aged
between 25 and 59 (average 41), who presented during
1995–2001 with arthritis of unknown origin. All were
found to have a positive presenting a positive parvovirus
B19 PCR as evaluated by synovial membrane biopsy taken
by needle-arthroscopy. Fifteen patients could be re-exam-
ined; one patient moved away and one reported suVering
from chronic reactive arthritis due to an urogenital infection
with Chlamydia trachomatis. The patients were inter-
viewed about their medical history, underwent clinical
examination and a blood sample was carried out for serol-
ogy and PCR at baseline.
Five of 17 (35%) showed a joint eVusion and aspiration
was carried out. A second synovial biopsy was taken in one
patient undergoing arthroscopic synovectomy. No other
biopsies were carried out due to ethical reasons and lack of
therapeutic consequences as well.
The following laboratory tests were performed: ESR,
CRP, rheumatoid factor and the anti-CCP (anti-cyclic cit-
rullinated peptid), IgG- and IgM-antibodies against parvo-
virus B19 and PCR of B19 DNA. The joint Xuid was also
tested for virus-DNA by PCR.
The presence of parvovirus B19 DNA was assessed by
PCR as described by Cassinotti et al. [12] for acute phase
specimen and by Aberham et al. [13] for reconvalesent
phase specimen. The latter procedure is validated according
to the current guidelines of the International Conference on
Harmonization [14] and the Council of Europe [15]. Parvo-
virus B19 speciWc antibodies were detected by Elisa
(Denka Seiken, Tokyo, Japan).
Results
The DNA tested by PCR was negative in all 17-blood sam-
ples. The Anti-B19-IgM indicating an acute infection was
negative in all cases at the Wrst and follow up visit as well.
The Anti-B19-IgG, however, proving a previous virus con-
tact, were positive in all cases at baseline. The CRP was
elevated in four patients (one RA, one Psoriatic arthritis,
one chronic unclassiWed arthritis and one patient with Lyme
arthritis treated 8 years ago). No virus genome was found in
the Wve joint Xuids. Parvovirus B19 DNA was again
detected by PCR 6 years after the Wrst positive result in the
synovial biopsy of one patient (only this patient was exam-
ined on the occasion of a surgical synovectomy) (Tables 1, 2).
The Wve patients with unclassiWed arthritis still showed
joint inXammation during follow up demonstrating the
same pattern as found at baseline. Four of these showed a
symmetric polyarthritis and one a monarthritis of the knee.
Of 17 (100%) cases of arthritis with positive parvovirus
B19 DNA in the synovial tissues, 9 cases (53%) remained
unclear. Four of these nine cases (23.5%) underwent com-
plete remission with an average 15 months and Wve cases
(29.4%) had persistent arthritis over a mean of 6.5 years.
Eight patients (47%) could be classiWed as follows: in
three patients (17,6%) a reactive arthritis following a gas-
trointestinal infection was diagnosed. In one of these cases
Salmonella typhimurium (positive faecal test) and in
another case no pathogen was detected. An infection-
related arthritis after an infection with E. histolytica was
assumed in one patient (positive faecal test) [2–4, 16]. All
of them showed complete remission within 6 months (aver-
age disease duration 4.3 months). Lyme arthritis with posi-
tive serology and DNA PCR of Borrelia burgdorferi was
found in three cases (17.6%). All three cases recovered
after antibiotic therapy within 3–8 months. One patient
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(5.9%) was diagnosed as psoriatic arthritis when character-
istic skin manifestations appeared 3 months after disease
onset. One patient (5.9%) developed erosive rheumatoid
arthritis with a positive anti-CCP titer but negative rheuma-
toid factor.
Discussion
The diagnosis of parvovirus arthritis is easily missed
because the typical viral exanthema is best known to pedia-
tricians, while the associated joint complaints occur primar-
ily in adults, often without skin involvement [17]. Failure to
obtain parvovirus B19 serology at the time of arthritis pre-
sentation may leave the early diagnostic IgM antibody
response undetected. On the other hand, persistent joint
activity in later stage disease is more diYcult to classify
[18]. While the seroprevalence of B19 IgG in the adult pop-
ulation is 40–60%, such positive IgG titers are non-speciWc
and do not necessarily imply a recent infection [19]. PCR
has been used diagnostically for detection of B19 DNA in
many diVerent clinical specimens [12, 20]. The value of the
presence of B19 DNA in the synovial membrane for the
diagnosis of B19 associated arthritis is controversial. There
are reports of detectable B19 DNA in joint samples of
patients with chronic juvenile arthritis, in healthy individu-
als with joint damage due to trauma [7], in patients with
rheumatoid arthritis and osteoarthritis [9, 10].
In this follow-up study of arthritis patients with a posi-
tive synovial biopsy for B19 DNA at entry nearly half of
them could be classiWed as Lyme disease, reactive arthritis,
psoriatic arthritis and rheumatoid arthritis. In these patients
the detection of viral genome does probably not prove the
viral aetiology of the joint inXammation.
In 53% of patients the arthritis remained unclassiWed.
Forty Wve percent of these arthritis healed spontaneously
without signs of joint damage within several months or a
few years respectively. B19 DNA in blood samples and
synovial Xuid was detected in one patient at the Wrst exami-
nation and became negative in the follow-up. Either syno-
vial biopsies nor bone marrow aspirations were taken in all
these asymptomatic people therefore no information about
the B19 genome status were available. Despite other clini-
cal or laboratory Wndings these patients have been sug-
gested to have a probable diagnosis of B19 associated
arthritis.
The other 55% showed a chronic persistence of synovial
inXammation mostly over a couple of years without joint
destruction or symptoms of other organ systems or of the
skin. All patients except one (monarthritis of the knee joint)
showed symmetric polyarthritis of small and large joints.
Chronic B19 arthropathies over months to years are
described [21, 22]. In these cases most commonly the small
joint of the hands, feet, wrists, knees and ankles symmetri-
cally were involved mimicking early RA. The development
of erosions or nodules is rarely reported [23, 24]. Since
human parvovirus B19 infection is common and the clinical
picture of early RA and B19 arthritis may be undistinguish-
able some cases might be the result of a coincidence of the
two diseases. No information about B19 DNA detected by
Table 1 Clinical data, Parvovirus B 19 infection markers in sera, synovial samples and bone marrow at study entry (1995–2001)
Patient 
number
Sex Age Arthritis Serum IgG 
Anti-B19
Serum IgM 
Anti-B19
Blood 
B19 DNA
CRP 
(n < 5mg/l)
Synovial Xuid 
B19 DNA
Synovial biopsy 
B19 DNA
Bone marrow 
B19 DNA
1 M 29 Poly Pos Neg Pos 69 Neg Pos Neg
2 F 44 Mono (knee) Pos Neg Neg Normal Neg Pos Neg
3 F 33 Poly Pos Neg Neg Normal Neg Pos Pos
4 F 37 Mono (knee) Pos Neg Neg Normal Neg Pos Neg
5 M 31 Mono (knee) Pos Neg Neg 61 Neg Pos Neg
6 F 43 Poly Pos Neg Neg 55 Neg Pos –
7 F 48 Mono (knee) Pos Neg Neg 18 Neg Pos Pos
8 M 28 Oligo Pos Neg Neg 63 Neg Pos Neg
9 M 37 Oligo Pos Neg Neg Normal Neg Pos Neg
10 F 29 Poly Pos Neg Neg 14 Neg Pos –
11 F 19 Poly Pos Neg Neg Normal Neg Pos –
12 F 53 Poly Pos Neg Neg Normal Neg Pos Pos
13 M 33 Mono Pos Neg Neg 38 Neg Pos Pos
14 F 23 Oligo Pos Neg Neg 25 Neg Pos Pos
15 F 28 Poly Pos Neg Neg Normal Neg Pos Pos
16 M 44 Poly Pos Neg Neg 39 Neg Pos Pos
17 F 41 Mono (knee) Pos Neg Pos Normal Pos Pos Pos
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PCR in synovial samples or bone marrow were available in
these reports. The signiWcance of parvovirus B19 DNA in
the synovium of established RA patients still remains con-
troversial [9, 25, 26]. It was hypothesized that a proportion
of patients with a diagnosis of seronegative RA and a few
patients with rheumatoid factor positive RA that has a begin
anerosive course, have chronic parvovirus B19 arthropathy
[27]. A second synovial biopsy in one of our chronic
patients revealed B19 DNA indicating persistence of either
B19 virus or at least select B19 DNA sequences in the joint.
In all other cases B 19 DNA could not be detected either in
synovial Xuid or in blood samples during follow-up.
The fact that during follow-up no samples of synovial tis-
sue and bone marrow were taken represents a limitation our
study. It would have been of interest to know whether DNA
sequences of the virus can still be identiWed in the synovial
membrane in the remaining cases of persisting arthritis.
However, due to ethical reasons and lack of therapeutic con-
sequences these tissue samples were not available any more.
In summary, the value of parvovirus B19 genome detection
in the synovial tissue in an occasional arthritis patient is still
unclear. If the arthritis remains unclassiWed a positive result
of B19 DNA of the synovium in patients with Anti-B19 IgG
antibodies can indicate a virus-induced arthritis with a
favourable outcome. Even in patients with persistent arthri-
tis synovial B19 DNA along with a serological Anit-B19
IgG response may not be diagnostic.
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